The major response which is the presence of BCR-ABL fusion cells less than 15% was observed in 7 patients, and minor response which is the presence BCR-ABL cells (16-50%) was observed in 4 patients, while no response against the drug which is the presence of BCR-ABL fusion genes (60-100%) was detected in 8 CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.